AcquisitionsAug 6, 2026, 06:16 PM
Biogen Completes Acquisition of RayThera Inc.
AI Summary
Biogen Inc. announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company specializing in small-molecule therapies for immunology. This acquisition is expected to strengthen Biogen's growing immunology portfolio by adding multiple assets, with the lead program having entered Phase 1 development in July 2026. Biogen views this as a strategic move to diversify its pipeline and drive long-term growth.
Key Highlights
- Biogen completed the acquisition of RayThera Inc.
- RayThera Inc. is a privately held biotechnology company focused on immunology.
- The acquisition strengthens Biogen's immunology portfolio with multiple assets.
- RayThera's lead program entered Phase 1 development in July 2026.
- The acquisition supports Biogen's strategy for long-term growth and pipeline diversification.
Price Impact
More from BIIB